Prime Medicine (PRME) Current Leases (2021 - 2026)
Prime Medicine's (PRME) quarterly Current Leases came in at $8.5 million in Q1 2026, up 24.61% YoY from $6.9 million in Q1 2025, and up 5.03% on a QoQ basis from $8.1 million in Q4 2025.
Prime Medicine (PRME) Current Leases (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Current Leases data on file, last reported at $8.5 million in Q1 2026.
- Quarterly Current Leases rose 24.61% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (up 24.61% YoY) and the FY2025 annual result came in at $8.1 million, up 125.15% from the prior year.
- Current Leases advanced to $8.5 million in Q1 2026, from $8.1 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $13.5 million in Q2 2023 to a low of $3.6 million in Q4 2024.
- A 5-year average of $8.5 million and a median of $8.1 million in 2025 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2024 — Current Leases tumbled 61.39% — and 2025, when it jumped 125.15%.
- Tracing PRME's Current Leases over 5 years: stood at $11.7 million in 2022, then dropped by 20.68% to $9.3 million in 2023, then slumped by 61.04% to $3.6 million in 2024, then jumped by 125.15% to $8.1 million in 2025, then grew by 5.03% to $8.5 million in 2026.
- The last three Current Leases figures came in at $8.5 million (Q1 2026), $8.1 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 8.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.97 Mn |
| Mar 31, 2026 | 8.55 Mn |
| Dec 31, 2025 | 8.14 Mn |
| Sep 30, 2025 | 7.71 Mn |
| Jun 30, 2025 | 7.26 Mn |
| Mar 31, 2025 | 6.86 Mn |
| Dec 31, 2024 | 3.61 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Mar 31, 2024 | 6.75 Mn |
| Dec 31, 2023 | 9.28 Mn |
| Sep 30, 2023 | 11.22 Mn |
| Jun 30, 2023 | 13.51 Mn |
| Mar 31, 2023 | 11.77 Mn |
| Dec 31, 2022 | 11.69 Mn |
| Sep 30, 2022 | 11.58 Mn |
| Dec 31, 2021 | 7.34 Mn |